- United States
- /
- Medical Equipment
- /
- NYSE:BLCO
Bausch + Lomb Third Quarter 2024 Earnings: Beats Expectations
Bausch + Lomb (NYSE:BLCO) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$1.20b (up 19% from 3Q 2023).
- Net income: US$4.00m (up from US$84.0m loss in 3Q 2023).
- Profit margin: 0.3% (up from net loss in 3Q 2023).
- EPS: US$0.006 (up from US$0.24 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bausch + Lomb Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Bausch + Lomb's balance sheet and an in-depth analysis of the company's financial position.
Valuation is complex, but we're here to simplify it.
Discover if Bausch + Lomb might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:BLCO
Bausch + Lomb
Operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.
Undervalued with moderate growth potential.